Merck (MRK) Retained Earnings (2009 - 2026)

Merck (MRK) reported Retained Earnings of $66.7 billion for Q1 2026, up 1443.83% year-over-year from $4.3 billion in Q1 2025, and down 8.7% quarter-over-quarter from $73.1 billion in Q4 2025.

Merck (MRK) Retained Earnings (2009 - 2026) Analysis & Trends

Merck (MRK) has 18 years of Retained Earnings data on file, last reported at $66.7 billion in Q1 2026.

  • Retained Earnings for Q1 2026 came in at $66.7 billion, up 1443.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $66.7 billion (up 1443.83% YoY), and the FY2025 annual result was $73.1 billion, up 1577.76% from the prior year.
  • Retained Earnings retreated to $66.7 billion in Q1 2026 per MRK's latest filing, from $73.1 billion in the prior quarter.
  • Over five years, Retained Earnings peaked at $73.1 billion in Q4 2025 and troughed at -$5.4 billion in Q2 2024.
  • A 5-year average of $38.4 billion and a median of $56.3 billion in 2022 frame the typical range for Retained Earnings.
  • The sharpest annual moves came in 2024 and 2025: Retained Earnings sank 109.89% in 2024, then jumped 1577.76% in 2025.
  • A 5-year view of Retained Earnings shows it stood at $61.1 billion in 2022, then slipped by 11.76% to $53.9 billion in 2023, then sank by 109.18% to -$4.9 billion in 2024, then soared by 1577.76% to $73.1 billion in 2025, then slipped by 8.7% to $66.7 billion in 2026.
  • Business Quant data shows MRK's Retained Earnings at $66.7 billion in Q1 2026, $73.1 billion in Q4 2025, and $72.2 billion in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Retained Earnings (Qtr)
1 Gsk 92,316,836.42 Bn 92,316,831.46 Bn 7.76 Bn 1.90 Bn
2 Eli Lilly 983.57 Bn 978.29 Bn 16.22 Bn 29.51 Bn
3 Johnson & Johnson 553.56 Bn 531.50 Bn 15.96 Bn -14.83 Bn
4 AbbVie 383.35 Bn 374.00 Bn 10.78 Bn -17.87 Bn
5 Merck 281.71 Bn 276.06 Bn 12.09 Bn 66.72 Bn
6 Amgen 182.20 Bn 170.16 Bn 5.87 Bn -190.00 Mn
7 Gilead Sciences 153.71 Bn 145.98 Bn 5.52 Bn 78.00 Mn
8 Pfizer 143.75 Bn 130.98 Bn -1.21 Bn -7.20 Bn
9 Bristol Myers Squibb 109.71 Bn 99.25 Bn 8.07 Bn -1.37 Bn
10 Novartis Ag 108.28 Bn 107.60 Bn - -

Historic Data

Download Data
DateValue
Mar 31, 2026 66.72 Bn
Dec 31, 2025 73.08 Bn
Sep 30, 2025 72.23 Bn
Jun 30, 2025 68.48 Bn
Mar 31, 2025 -4.97 Bn
Dec 31, 2024 -4.95 Bn
Sep 30, 2024 61.38 Bn
Jun 30, 2024 -5.36 Bn
Mar 31, 2024 -5.27 Bn
Dec 31, 2023 53.90 Bn
Sep 30, 2023 57.08 Bn
Jun 30, 2023 54.20 Bn
Mar 31, 2023 -4.88 Bn
Dec 31, 2022 61.08 Bn
Sep 30, 2022 -4.74 Bn
Jun 30, 2022 58.44 Bn
Mar 31, 2022 56.25 Bn
Dec 31, 2021 53.70 Bn
Sep 30, 2021 51.69 Bn
Jun 30, 2021 -4.63 Bn